Our findings are supported by previous studies14,15 which also observed hypo- and hyper-methylated CpGs in the MHC class II region in MS patients in comparison to healthy controls and also in association with the HLA-DRB1*1501 genotype. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.